The Neuroendocrine Cancer community were invited to and took part in Cancer 52 second patient survey looking at the impact of the Covid-19 pandemic on people with rare and less common cancers ran from early December 2020 to mid-January 2021. Over 500 people, with a rare or less common cancer, from across England responded and Cancer 52 are publishing the findings this week.
Many thanks to all those members and patients who gave their help and time to support this valuable piece of work.
Cancer 52 will be sharing the findings with NHS England, and other key stakeholders in the charity sector and industry.
You can read the full survey report on the Cancer 52 website here.